Stock Report: Galena Biopharma Inc. (GALE) Report Updated: May 20, 2013 | Print This Page

Galena Biopharma, Inc., a biotechnology company, engages in discovering, developing, and commercializing innovative therapies addressing unmet medical needs using targeted biotherapeutics. The company develops cancer therapeutics using peptide-based immunotherapy products, including its lead product candidate NeuVax (nelipepimut-S or E75), which is in Phase 3 PRESENT trial for the treatment of various cancers. It also develops Folate Binding Protein-E39, a targeted vaccine that is in Phase 1/2 clinical trial for the prevention of recurrence in gynecological cancers, such as ovarian, endometrial, and breast cancers. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Galena Biopharma, Inc. in September 2011. Galena Biopharma, Inc. was founded in 2003 and is based in Lake Oswego, Oregon.